Connect with us

Featured

This Healthcare Company Is Leading The Industry By Example

Daniel Chase

Published

on

stock_price_cannabis

Every once in a great while, society takes an impressive step forward. Over the years this process has looked different but the outcomes have always remained the same: progress is progress. The invention of the assembly-line allowed for mass-production of products and goods that helped shape a world in need. Through the advent of the internet, the global community has become more connected than ever before. So what, then, will our next step be? I posit that the global healthcare framework is long overdue for some tender-loving care. 

Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond

According to recent global reports, over the course of the next decade, the global population will top 9 billion, indicating that it won’t be long before resources begin to lessen and access to healthcare and other social services may follow suit. Thankfully, companies amid the healthcare industry have wisened up these facts and are actively working to create solutions to combat the impending obstacles that face our world. 

Premier Health Group Inc (OTC:PHGRF) / (CSE:PHGI), a Canadian-based healthcare provider, is one such company putting in the work to lead the global healthcare industry into the future. Presently, Premier boasts a member network of over 3,000,000 (patients), with new members signing up on a near-daily basis. 

Despite the fact that research on the compound’s health benefits has been limited, millions of American consumers are obsessed with cannabidiol (CBD). Everyone from people with anxiety to those who suffer from bad headaches wants drinks, cookies, and beverages infused with CBD. This is largely due to the fact that in the last few years, we’ve seen a societal shift in perspective regarding cannabis and the stereotypes typically associated with the plant. Leading the healthcare industry by example, Premier Health Group Inc (OTC:PHGRF) / (CSE:PHGI) has made it clear their plans to launch a Cannabis Clinic and incorporate cannabis into its treatment options. 

Towards the tail-end of last month, Premier Health Group Inc (OTC:PHGRF) / (CSE:PHGI) announced that it had initiated integration of CB2 Insights’ (CBII.CN) medical cannabis Clinical Decision Support tool. For those unfamiliar with CB2, the Company operates 28 medical cannabis evaluation centers staffed with physicians and healthcare practitioners and creates both access for patients who qualify for medical cannabis as well as a center of excellence to study and understand the clinical outcomes of cannabinoid therapy.

Per the details of Premier Health Group Inc (OTC:PHGRF) / (CSE:PHGI)’s agreement with CB2 Insights, the deal will give more than 4600 physicians and healthcare practitioners using Premier Health’s Juno EMR platform access to the industry’s only medical cannabis-specific CDS tool. This first-of-its-kind integration in the medical cannabis sector will allow physicians and healthcare practitioners to overcome many of the barriers they face from a lack of access to education, qualification factors, risks and benefits of cannabinoid therapy, all on a patient-specific basis using clinically-validated data.

stock_price_AI

Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. As of 3/26/2019 Midam has been compensated an additional $100,000 by Premier Health Group for additional coverage without further extended coverage duration. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.Please click here for full disclaimer.

Continue Reading
Click to comment

Biotechnology

2 Biotech Stocks Turning Heads After Key Developments This Quarter

Joe Samuel

Published

on

biotech stocks to watch today

There are very few sectors in the stock market that have consistently produced winning trades. You might be able to count such sectors on one hand. Biotech is certainly among those sectors due to the emergence of highly innovative companies. These firms tend to create new avenues of creation to address unmet medical needs.

There are plenty of promising companies in the sector but it is necessary for an investor to do research thoroughly. It makes finding the best biotech stocks a bit easier. Though no one’s guaranteed a win, sifting out bad stocks is the key. One must watch the market closely to come across promising biotech stocks. Here is a look at two biotech stocks that are worth watching.

Biotech Stocks To Watch: Moleculin Biotech (MBRX)

The first biotech stock to consider is that of Moleculin Biotech Inc (NASDAQ:MBRX), which made some gains on Wednesday on the back of positive interim results for one of its products. The company, which is involved in manufacturing medicines meant for extremely resistant tumors, released data with regards to its acute myeloid leukaemia medicine annamycin.

top biotech stocks to buy

Moleculin revealed highly positive interim data from the Phase ½ clinical study of the medicine and naturally, it has resulted in a lot of excitement in the market with regards to the stock. The stock rose by as much as 2% on the back of the news in yesterday’s trading session. It is one of the key biotech stocks to keep an eye on over the coming days.

Biotech Stocks To Watch: Eyepoint Pharmaceuticals (EYPT)

The other biotech stock that has recorded impressive gains on the market today is the Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) stock. On Wednesday, the company announced an important deal with regard to dexamethasone intraocular suspension 9% (DEXYCU). Eyepoint announced that it has managed to reach an agreement with one of the biggest players in the U.S. integrated delivery systems.

[Read More] 3 Pharma Stocks To Watch In December 2019

The deal is for two years and the other party is going to offer DEXYCU in its aforesaid systems. It is a major boost for Eyepoint and it has resulted in 5% to close at $1.54 in Wednesday’s trading session.

best biotech stocks to watch today

Continue Reading

Featured

Stock Price Newsletter – December 6, 2019

Joe Samuel

Published

on

stock price newsletter

2 Biotech Stocks to Watch As The Sector Hits New High

The biotech sector has thrown plenty of winners over the course of the last decade or so and if experts are to be believed then it is going to continued to do so for the foreseeable future. Great advancements are being made in the biotech industry and many companies are working on a highly advanced product.

Continue Reading


Is It Time To Buy Or Sell Netflix; Streaming Wars Heat Up

The streaming wars have commenced this month with the launch of Disney Plus and Apple TV+. Many more services are going to be launched over the coming months and the sole purpose of these services is to topple the biggest name in the streaming services, Netflix Inc (NASDAQ:NFLX). The streaming giant has had a hard time this year, due to disappointing subscriber growth.

Click To Read More


Is ROKU Stock a Buy Or Hold on Disney, Apple & Streaming TV Growth?

The stock suffered a slump following its Q3 2019 financial results but since then it has regained much of the losses. While it is true that the losses widened from the year-ago period, experts believe that Roku is a stock that could have long term growth potential.

See For Yourself

Continue Reading

Biotechnology

2 Biotech Stocks to Watch As The Sector Hits New High

Joe Samuel

Published

on

best biotechnology stocks to buy sell

The biotech sector has thrown plenty of winners over the course of the last decade or so and if experts are to be believed then it is going to continued to do so for the foreseeable future. Great advancements are being made in the biotech industry and many companies are working on a highly advanced product.

In such a situation, it is imperative for an intelligent investor to look for companies worth investing in. One should watch the latest developments in the sector and track specific companies closely. Here is a look at two biotech stocks that are worth watching.

Neoleukin Therapeutics

top biotech stocks to watch list

The first biotech stock to watch is that of Neoleukin Therapeutics Inc (NLTX), which has managed to gain significantly over the past two weeks. On November 13, the company released its third-quarter results and since then it has rocketed by as much as 75%. The Canadian company made a loss of $59.1 million in the quarter, which worked out to $2.26 per share.

The company is a biopharmaceutical company that is involved in immunotherapies using de novo protein design technology. The company’s lead product candidate is NL-201, which is an amalgamation of both IL-2 and IL-15 and helps in removing alpha receptor binding.

Verastem

healthcare stocks to buy now

The other biotech stock that is worth watching is Verastem Inc (NASDAQ:VSTM). It made significant gains over the past week. On Monday, the company announced that it has submitted a Marketing Authorization Application for its product COPIKTRA to the European Medicines Agency.

COPIKTRA is a phosphoinositide 3-kinase. It’s meant for patients suffering from refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory follicular lymphoma (FL).

The company is seeking approval for the same in the European market. Verastem stated that it has seen significant improvement in patients who used the product. The stock rocketed by as much as 60% after the news broke and remains one of the stocks to watch this week.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com